Florencia Halperin,Robert G Dluhy
Florencia Halperin
Glucocorticoid-remediable aldosteronism (GRA) is a hereditary form of primary hyperaldosteronism and the most common monogenic cause of hypertension. A chimeric gene duplication leads to ectopic aldosterone synthase activity in the cortisol...
Gian Paolo Rossi
Gian Paolo Rossi
A few simple rules can allow physicians to successfully identify many patients with arterial hypertension caused by PA among the so-called essential hypertensive patients. The hyperaldosteronism and the hypokalemia can be cured with adrenal...
Samuel M Zuber,Vitaly Kantorovich,Karel Pacak
Samuel M Zuber
Pheochromocytoma is a tumor of the chromaffin cells in the adrenal medulla and sympathetic paraganglia, which synthesizes and secretes catecholamines. Norepinephrine, epinephrine, and dopamine all act on their target receptors, which causes...
Screening for adrenal-endocrine hypertension: overview of accuracy and cost-effectiveness [0.03%]
肾上腺-内分泌性高血压的筛查：准确性与成本效益概述
Gary L Schwartz
Gary L Schwartz
Formal studies have not been performed to assess the cost-effectiveness of screening strategies for endocrine causes of hypertension. However, an understanding of the diagnostic accuracy of available screening tests and the clinical setting...
Robert M Carey
Robert M Carey
Multiple hormonal factors play a major role in the functional and structural abnormalities of hypertension (HT). At present, the kidneys and, in particular, renal Na(+) retention are thought to constitute a primary and sustaining mechanism ...
Lawrence R Krakoff
Lawrence R Krakoff
Derek LeRoith
Derek LeRoith
Neuroendocrine tumors: current recommendations for diagnosis and surgical management [0.03%]
神经内分泌肿瘤的诊断和手术治疗的最新推荐意见
Saju Joseph,Yi-Zarn Wang,J Philip Boudreaux et al.
Saju Joseph et al.
Neuroendocrine tumors (NETs) are rare neoplasms found in diverse locations within the body. These tumors are commonly classified by the primary tumor's location, further subclassified by their differentiation, and finally segregated by thei...
Guillaume Nicolas,Giampiero Giovacchini,Jan Müller-Brand et al.
Guillaume Nicolas et al.
Targeted radiopeptide therapy with (90)Yttrium- or (177)Lutetium-labeled somatostatin analogs has been proven to improve significantly quality of life and survival in patients suffering from metastatic or unresectable neuroendocrine tumors ...
Somatostatin receptor-targeted radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors [0.03%]
生长抑素受体介导的核素治疗在胃肠胰神经内分泌肿瘤中的应用研究进展
Dik J Kwekkeboom,Wouter W de Herder,Eric P Krenning
Dik J Kwekkeboom
Treatment with radiolabeled somatostatin analogs is a promising tool in the management of patients with inoperable or metastasized neuroendocrine tumors. Symptomatic improvement may occur with all (111)Indium-, (90)Yttrium-, or (177)Lutetiu...